Thirty-four girls with precocious puberty (27 idiopathic, 6 cerebral, 1 McCune-Albright syndrome) were treated with cyproterone acetate (CPA) for 1.2-8.4 years (3.71 ± 0.31; mean ± SEM) at a daily dosage of 66-150 mg/m2 (103.7 ± 6.2). The mean chronological age (CA) and bone age at the beginning of treatment were 5.99 ± 0.31 and 8.6 ± 0.39 years, respectively, and 9.78 ± 0.19 and 12.44 ± 0.22 years, respectively, at the end of therapy. At the last evaluation, mean CA was 14.23 ± 0.4 years, and 32 girls had reached final height. The control group consisted of 10 girls with idiopathic precocious puberty who, at their parents’ request, were not treated. Mean CA at the onset of pubertal signs was 6.05 ± 0.25 years. All patients had reached final height at the time of the last observation. There was no significant difference between final height of treated (152.43 ± 1.36 cm) and untreated (149.55 ± 1.99 cm) girls. Final height was significantly lower than target height in both treated (155.08 ± 0.92 cm; p < 0.025) and untreated (156.45 ± 1.29 cm; p < 0.0005) patients, but the mean height of treated patients is nearer to target height than that of untreated ones. A positive correlation was found between final height and target height both in treated (p < 0.005) and untreated (p < 0.05) patients. After the discontinuation of CPA treatment all girls resumed the progressive course of puberty. Menstruation was regular and normal in 27 cases and irregular in the remaining 7, of whom 4 showed additional hormonal and clinical evidence of polycystic ovarian disease (PCOD). Menses were regular in 8 and irregular in 2 untreated patients, of whom 1 also showed PCOD. It is concluded that CPA treatment slightly improved the statural growth of patients with precocious puberty. The altered gonadal function observed in adulthood in these patients is probably not due to CPA administration. A longer follow-up is needed in patients with central precocious puberty in order to detect the presence of PCOD.

Keywords:
Precocious puberty, Cyproterone acetate treatment, Final height, Polycystic ovarian disease
This content is only available via PDF.
© 1992 S. Karger AG, Basel
1992
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.